Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2000, p. 183-185, Vol. 44, No. 1
Medical and Research Services, Veterans
Affairs Medical Center, and Division of Infectious Diseases, Oregon
Health Sciences University, Portland, Oregon
Received 21 June 1999/Returned for modification 13 August
1999/Accepted 11 October 1999
A deletion mutation (codons 595 to 603) in the cytomegalovirus
(CMV) UL97 gene was recently reported after sequence analysis of
leukocyte DNA from a patient receiving ganciclovir. The corresponding viral phenotype was examined by transfer of this mutation to a laboratory CMV strain (strain Towne). The recombinant virus was resistant to ganciclovir (8.4-fold increase in the 50% inhibitory concentration), was sensitive to foscarnet, and replicated normally in
cell culture.
Drug resistance that develops after
prolonged ganciclovir therapy for human cytomegalovirus (CMV) infection
usually involves a mutation in the viral UL97 phosphotransferase gene
(3). UL97 is responsible for the initial phosphorylation of
the drug, which is necessary for its antiviral activity
(15). Mutations in the CMV DNA polymerase gene may also
contribute to ganciclovir resistance (6, 7, 9).
Previous studies have documented that mutations at UL97 codons 460, 520, and 591 to 607 are associated with ganciclovir resistance in
clinical CMV isolates (1-6, 10), with amino acid
substitutions at codons 460, 594, and 595 being the most common
(4, 5). Deletion mutations conferring ganciclovir resistance
are relatively unusual. Reported cases include a one-codon deletion at
codon 595 (2) and a four-codon deletion (codons 590 to 593 or 591 to 594) (5, 15). Recently, a nine-codon deletion
(UL97 codons 595 to 603) was detected in DNA extracted from leukocytes
and colon tissue of a renal transplant recipient after prolonged
exposure to ganciclovir (12). Although this mutation was
associated with treatment-resistant CMV disease, no viral isolate was
available from this patient to confirm the drug resistance phenotype
that was suspected to be conferred by this mutation. Additionally, because this was the largest UL97 deletion that had been reported in a
clinical specimen, the question of its replication competence arose,
since UL97 activity appears to be necessary for normal CMV replication
and laboratory mutants containing large deletions in UL97 are either
difficult to make or are very much attenuated (13, 14). We
therefore performed experiments to transfer the deletion from codons
595 to 603 into a laboratory CMV strain (strain Towne) in order to
examine its associated phenotype.
The transfer of the deletion into CMV Towne (VR-977; American Type
Culture Collection, Manassas, Va.) was performed by homologous recombination as published previously (4). The virus was
propagated in human fibroblasts, and Towne DNA was extracted from
culture supernatants by ultracentrifugation and lysis of the viral
pellet with sodium dodecyl sulfate and proteinase K, followed by
phenol-chloroform extraction and ethanol precipitation (4).
A PCR product (PCR41999) containing a segment of the CMV UL97 gene
(from codon 510 onward) was amplified from a leukocyte extract of the
patient previously reported to have the UL97 deletion from codons 595 to 603 (12). The PCR primers were CPT1528
(5'-AACTGCTCGCACCGTCTGCGC-3') and CPTY
(5'-GGTGAGCTCCTCATCGTCGTCG-3'). PCR41999 was digested with restriction enzymes PstI and XhoI, taking
advantage of naturally occurring restriction sites within PCR41999
corresponding to nucleotides 142070 and 142713, respectively, of the
published complete CMV sequence (GenBank accession no. X17403). The
resulting 0.64-kb fragment was isolated by agarose gel
electrophoresis and was cloned into Bluescript vector pBS2KS+
(Stratagene, La Jolla, Calif.), forming plasmid pZC32 (Fig.
1). A 4.7-kb segment of the Towne genome,
corresponding to nucleotides 139690 to 144436 of the complete CMV
sequence (Genbank accession no. X17403) and incorporating the
UL97-coding sequence, was subcloned from cosmid Tn26
(11) by digestion with restriction enzymes NotI
and KpnI, followed by preparative agarose gel
electrophoresis and ligation into vector pBS2KS+, forming plasmid pZC33
(Fig. 1). The UL97 segment of pZC32 containing the deletion from codons
595 to 603 was then swapped into pZC33 (Fig. 1), forming pZC34.
Homologous recombination was achieved by cotransfection of 20 µg of
Towne DNA and 2 µg of pZC34 digested with NotI and
KpnI into subconfluent human foreskin fibroblast monolayers
by the calcium phosphate precipitation method (4). A viral
cytopathic effect was noted at 9 days posttransfection, and the
resulting extracellular virus was propagated twice in the presence of
20 µM ganciclovir and was then plaque purified once in the presence
of 20 µM ganciclovir and twice in the presence of no drug.
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
A Nine-Codon Deletion Mutation in the
Cytomegalovirus UL97 Phosphotransferase Gene Confers Resistance
to Ganciclovir
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
View larger version (18K):
[in a new window]
FIG. 1.
Strategy for construction of CMV recombinant containing
the deletion from codons 595 to 603.
The entire 2.1-kb UL97-coding sequence and the 3.7-kb DNA polymerase-coding sequence of plaque-purified (three times) virus T963-5-6-2 were sequenced by PCR amplification and multiple fluorescent dideoxy sequencing reactions (6). The DNA polymerase-coding sequence was identical to that of the Towne strain (GenBank accession no. D14980), and the UL97-coding sequence had no amino acid changes compared with the sequence of the Towne strain (GenBank accession no. U07355) other than the deletion from codons 595 to 603. The presence of the same deletion as in pZC34, along with absence of any other mutations in UL97 or DNA polymerase, the only known CMV genes that affect ganciclovir susceptibility, was interpreted as evidence that the deletion confers ganciclovir resistance, similar to conclusions drawn from results of studies of other UL97 marker transfers (1-4, 6, 10).
Cell culture susceptibility testing by plaque reduction (8) of recombinant virus T963-5-6-2, simultaneously performed three times with a wild-type Towne strain as a control, gave a mean ganciclovir 50% inhibitory concentration (IC50) of 24.4 µM (standard deviation [SD], 2.9 µM) and a mean foscarnet IC50 of 119 µM (SD, 31.5 µM). The mean ganciclovir IC50 for the Towne control virus was 3.1 µM (SD, 1.2 µM), and the mean foscarnet IC50 was 91 µM (SD, 9.6 µM). The ganciclovir IC50 for the recombinant virus was 8.4-fold (SD, 2.7-fold) increased over that for the Towne control strain, whereas the foscarnet IC50 was 1.3-fold that for the Towne control strain; the difference was considered to be not statistically significant. The degree of ganciclovir resistance is similar to the 7- to 10-fold increases reported previously for UL97 mutants (4, 6) and higher than the 3.5- to 5.3-fold increases reported for DNA polymerase mutants (6, 7).
The recombinant virus T963-5-6-2 was observed to form normal-sized plaques and a cytopathic effect in fibroblast culture; the plaque sizes and cytopathic effects are comparable to those of the Towne strain at the same intervals postinfection. After inoculation of 7 × 105 fibroblasts with the same number of PFU of T963-5-6-2 or the Towne strain control, the virus titers in the supernatant were comparable at several time points afterward, as assayed by plaque titration on fibroblast monolayers (Fig. 2). We therefore conclude that the recombinant virus retains full replication competence.
|
Results of this study strengthen the current impression (3) that mutations at codons 460, 520, and 591 to 607 (or possibly slightly beyond codon 607) confer ganciclovir resistance and that genotypic screening of UL97 for ganciclovir resistance should focus on this relatively limited range of codons. Furthermore, since CMV strains with deletions of either codons 591 to 594 (15) or codons 595 to 603 appear to be fully replication competent, the range of codons from codons 591 to 607 seems to be dispensable for the normal kinase function of UL97, while it strongly affects ganciclovir phosphorylation. We may expect the continued occasional appearance of clinical isolates with various deletions over the range from codons 591 to 607. The frequency of such mutations cannot be high given the number of resistant isolates that have been analyzed (3), but their existence should be taken into account in the design of genotypic assays.
| |
ACKNOWLEDGMENTS |
|---|
We thank Gail Marousek, Wei Zhang, and Matthew Shiveley for technical assistance, Carlos Paya (12) for referring the clinical specimen, and George Kemble (11) for providing cosmid Tn26.
This work was supported by U.S. Department of Veterans Affairs Research Funds and by NIH grant AI39938.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Infectious Disease Section P3ID, VA Medical Center, 3710 SW US Veterans Hospital Rd., Portland, OR 97201. Phone: (503) 273-5185. Fax: (503) 273-5348. E-mail: chous{at}ohsu.edu.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Baldanti, F., E. Silini, A. Sarasini, C. L. Talarico, S. C. Stanat, K. K. Biron, M. Furione, F. Bono, G. Palu, and G. Gerna. 1995. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol. 69:796-800[Abstract]. |
| 2. |
Baldanti, F.,
M. R. Underwood,
C. L. Talarico,
L. Simoncini,
A. Sarasini,
K. K. Biron, and G. Gerna.
1998.
The Cys607 Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients.
Antimicrob. Agents Chemother.
42:444-446 |
| 3. | Chou, S. 1999. Antiviral drug resistance in human cytomegalovirus. Transplant. Infect. Dis. 1:105-114[CrossRef][Medline]. |
| 4. | Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583[Medline]. |
| 5. | Chou, S., S. Guentzel, K. R. Michels, R. C. Miner, and W. L. Drew. 1995. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J. Infect. Dis. 172:239-242[Medline]. |
| 6. | Chou, S., G. Marousek, S. Guentzel, et al. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789[Medline]. |
| 7. |
Cihlar, T.,
M. D. Fuller, and J. M. Cherrington.
1998.
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
J. Virol.
72:5927-5936 |
| 8. | Drew, W. L., R. Miner, and E. Saleh. 1993. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin. Diagn. Virol. 1:179-185[CrossRef][Medline]. |
| 9. | Erice, A., C. Gil-Roda, J. L. Perez, et al. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092[Medline]. |
| 10. | Hanson, M. N., L. C. Preheim, S. Chou, C. L. Talarico, K. K. Biron, and A. Erice. 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39:1204-1205[Abstract]. |
| 11. | Kemble, G., G. Duke, R. Winter, and R. Spaete. 1996. Defined large scale alteration of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J. Virol. 70:2044-2048[Abstract]. |
| 12. | Mendez, J. C., I. G. Sia, K. R. Tau, M. J. Espy, T. F. Smith, S. Chou, and C. V. Paya. 1999. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 67:755-757[CrossRef][Medline]. |
| 13. | Michel, D., I. Pavic, A. Zimmermann, E. Haupt, K. Wunderlich, M. Heuschmid, and T. Mertens. 1996. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 70:6340-6346[Abstract]. |
| 14. |
Prichard, M. N.,
N. Gao,
S. Jairath,
G. Mulamba,
P. Krosky,
D. M. Coen,
B. O. Parker, and G. S. Pari.
1999.
A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency.
J. Virol.
73:5663-5670 |
| 15. | Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164[CrossRef][Medline]. |
Antimicrobial Agents and Chemotherapy, January 2000, p. 183-185, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fukui, Y., Shindoh, K., Yamamoto, Y., Koyano, S., Kosugi, I., Yamaguchi, T., Kurane, I., Inoue, N.
(2008). Establishment of a Cell-Based Assay for Screening of Compounds Inhibiting Very Early Events in the Cytomegalovirus Replication Cycle and Characterization of a Compound Identified Using the Assay. Antimicrob. Agents Chemother.
52: 2420-2427
[Abstract] [Full Text] -
Scott, G. M., Weinberg, A., Rawlinson, W. D., Chou, S.
(2007). Multidrug Resistance Conferred by Novel DNA Polymerase Mutations in Human Cytomegalovirus Isolates. Antimicrob. Agents Chemother.
51: 89-94
[Abstract] [Full Text] -
Lee, G.-C., Lee, D.-G., Choi, S.-M., Yoo, J.-H., Park, S.-H., Choi, J.-H., Min, W.-S., Cho, O.-H., Lee, C.-H., Shin, W.-S.
(2005). Use of Time-Saving Flow Cytometry for Rapid Determination of Resistance of Human Cytomegalovirus to Ganciclovir. J. Clin. Microbiol.
43: 5003-5008
[Abstract] [Full Text] -
Hantz, S., Michel, D., Fillet, A.-M., Guigonis, V., Champier, G., Mazeron, M.-C., Bensman, A., Denis, F., Mertens, T., Dehee, A., Alain, S.
(2005). Early Selection of a New UL97 Mutant with a Severe Defect of Ganciclovir Phosphorylation after Valaciclovir Prophylaxis and Short-Term Ganciclovir Therapy in a Renal Transplant Recipient. Antimicrob. Agents Chemother.
49: 1580-1583
[Abstract] [Full Text] -
Gilbert, C., Boivin, G.
(2005). Human Cytomegalovirus Resistance to Antiviral Drugs. Antimicrob. Agents Chemother.
49: 873-883
[Full Text] -
Baldanti, F., Gerna, G.
(2003). Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact. J Antimicrob Chemother
52: 324-330
[Abstract] [Full Text] -
Wolf, D. G., Yaniv, I., Ashkenazi, S., Honigman, A.
(2001). Emergence of Multiple Human Cytomegalovirus Ganciclovir-Resistant Mutants with Deletions and Substitutions within the UL97 Gene in a Patient with Severe Combined Immunodeficiency. Antimicrob. Agents Chemother.
45: 593-595
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»